Your thinking that VX-222 was a protease inhibitor would please VRTX greatly! That’s because VRTX’s recent message to the investment community is that VX-222 is unique among HCV drugs insofar as it has PI-like efficacy while having a resistance profile that is synergistic with PI’s—i.e. the best of both worlds.
Market Data 
Markets 
AI
